Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Visit Frequency Strategies for Antidepressant Trials
NCT02082392Phase 4Completed
- Sponsor
- New York State Psychiatric Institute
- Start
- Sep 2012
- Primary completion
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of escitalopram in major depressive disorder (MDD) (4 arms), sponsored by New York State Psychiatric Institute. Primary endpoint: Hamilton Rating Scale for Depression at 8 weeks. Started Sep 2012; status: completed.
02
Drugs
escitalopram
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02082392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02082392.